Do you ever withhold adjuvant RT after BCS in older women with stage I triple positive/Luminal-Her2 subtype breast cancers?
Her2 status was not evaluated as part of the PRIME 2 or CALGB trials and luminal Her2 patients likely represent a small minority of those enrolled in these trials, so how applicable are these data to such patients?
1 Answer
Mednet MemberInvited Expert
Radiation Oncology · New York University School of Medicine
Answered on
If they receive herceptin-based chemotherapy, then local regional recurrence rates are similar to luminal A disease (excellent review on this subject by Wendy Woodward during her talk at ASTRO in 2016- accessible on virtual meeting). So by that logic, you could consider it in someone who has receive...
Join for free or sign in to see the full answer